Categories
Archives
- 2026
- 2025
- 2024
- 2023
- 2022
- 2021
Dec
04
UCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting
Dec
03
Bridging Strategy and Innovation: Leadership in Action through the AES BRIDGE Program
Nov
14
When Every Second Matters
Nov
04
Elevating the lives of people impacted by thymidine kinase 2 deficiency (TK2d)
Nov
03
U.S. FDA approves KYGEVVI™ (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)
Oct
31
Redefining Hidradenitis Suppurativa (HS) Care Through Community and Collaboration
Oct
31
BIMZELX® (bimekizumab-bkzx) Data in Hidradenitis Suppurativa Showed Improvements in Pain and Resolution of Draining Tunnels Sustained to Three Years
Oct
29
UCB opens applications for 2026 UCB Myasthenia Gravis Scholarship™
Oct
29
UCB to unveil new data for RYSTIGGO® (rozanolixizumab-noli) and ZILBRYSQ®(zilucoplan) for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific Session
